3Lun·

$SDZ (+1,18 %) - Convincing quarterly figures from Sandoz


The generics manufacturer generated sales of $2.6 billion in the second quarter of 2024, which corresponds to an increase of 9% in constant currencies. In the first half of 2024, sales rose by 7% to $5.0 billion. The biosimilar business in particular grew by 29%. Based on the positive business performance, Sandoz has raised its full-year sales growth guidance to a mid to high single-digit range in constant currencies.


Own position:

38 shares at 27.60


Happy Investing

GG

1
Únase a la conversación